BET1L Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, featuring disruption of the BET1L gene. The polyclonal format provides a heterogeneous pool of knockout cells generated through CRISPR/Cas9-mediated gene editing, enabling loss-of-function studies of BET1L in a physiologically relevant epithelial context. This knockout model is designed for investigating endoplasmic reticulum-to-Golgi trafficking, SNARE complex function, and secretory pathway dynamics.
The A-549 cell line, originally isolated from lung adenocarcinoma tissue of a 58-year-old male, serves as a widely used in vitro model for lung adenocarcinoma research. These cells retain key characteristics of alveolar type II epithelium and are employed in studies of respiratory epithelial biology, cancer cell signaling, and drug response. The adherent epithelial morphology and robust secretory activity of A-549 cells make them particularly suitable for examining the impact of BET1L disruption on Golgi organization and protein secretion.
BET1L encodes a SNARE protein that mediates vesicle docking and fusion between the endoplasmic reticulum (ER) and Golgi apparatus. It forms a fusogenic SNARE complex by interacting with STX5, GOSR2, and SEC22B, facilitating anterograde cargo transport within the early secretory pathway. BET1L function is positioned downstream of the COPII coat assembly (comprising SAR1, SEC23/SEC24, and SEC13/SEC31) and upstream of COPI-mediated retrograde transport. Its activity is regulated by the ER stress response via transcription factors ATF6 and XBP1, linking secretory pathway integrity to cellular stress signaling. Downstream, BET1L-dependent trafficking influences the localization and function of Golgi-resident enzymes, secretory proteins, and plasma membrane proteins critical for cell communication and adhesion.
In the context of A-549 lung adenocarcinoma cells, BET1L knockout provides a valuable tool to dissect the role of ER-Golgi trafficking in cancer cell biology. Aberrant secretory activity and Golgi reorganization are hallmarks of cancer, contributing to altered glycoprotein synthesis, enhanced migration, and drug resistance. Disrupting BET1L in this model can reveal dependencies of lung cancer cells on efficient secretory pathway function, potentially uncovering vulnerabilities related to the unfolded protein response (UPR) or metabolic adaptation. Moreover, since BET1L is implicated in neurological disorders, but its role in non-neuronal tissues is less understood, this model enables comparative studies of SNARE complex composition and regulation in epithelial cancer cells.
Typical experimental applications include monitoring Golgi morphology by immunofluorescence using markers such as GM130 or giantin, assessing global protein secretion via glycoproteomics or luciferase-based secretion assays, and quantifying UPR gene expression by RT-qPCR. The polyclonal knockout cells are compatible with Western blotting to confirm loss of BET1L protein and evaluate compensatory changes in SNARE partners. Functional assays such as wound-healing migration or Matrigel invasion can be employed to assess the impact of BET1L disruption on metastatic properties. Drug sensitivity profiling with chemotherapeutic agents or ER stress inducers provides insights into the contribution of secretory pathway integrity to treatment response in lung adenocarcinoma. For additional information, please contact Ascent Research.
